Current clinical outcomes cannot determine conversion of SCA mutation carriers to manifest ataxia

This study, the first to determine the conversion rate of spinocerebellar ataxia (SCA) mutation carriers to manifest ataxia, shows that available clinical outcome parameters lack sensitivity in the premanifest phase.